Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | F12 | P00748 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30252198 | 1.00 | IDO1 (0.50) | IDO1HTTALDH1A1PIN1BLM | |
| SCHEMBL3812210 | 1.00 | IDO1 (0.50) | IDO1HTTALDH1A1PIN1BLM | |
| SCHEMBL5732694 | 1.00 | IDO1 (0.50) | IDO1HTTALDH1A1PIN1BLM | |
| SCHEMBL177082 | 1.00 | IDO1 (0.50) | IDO1HTTALDH1A1PIN1BLM | |
| Bromide SCHEMBL3727457 | 0.98 | IDO1 (0.49) | IDO1HTTALDH1A1PIN1BLM | |
| Hydrochloric Acid SCHEMBL3726157 | 0.98 | IDO1 (0.51) | IDO1HTTALDH1A1PIN1BLM | |
| SCHEMBL5848583 | 0.95 | PIN1 (0.46) | IDO1HTTALDH1A1PIN1BLM | |
| Pyridine SCHEMBL15822102 | 0.89 | F2 (0.48) | IDO1HTTALDH1A1PIN1MEN1 | |
| Trifluoroacetic Acid SCHEMBL3722523 | 0.89 | HTT (0.45) | IDO1HTTALDH1A1PIN1MEN1 | |
| SCHEMBL2475968 | 0.89 | PIN1 (0.58) | IDO1PIN1SIRT1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4301736-B1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2025-10-08 | — | — | EP | claimed |
| CN-120119268-A | Synthesis method of chiral 1-tetrahydronaphthalene amide compound | 南开大学 | 2025-06-10 | — | — | CN | claimed |
| EP-3897842-B1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2025-01-29 | — | — | EP | claimed |
| CN-120119268-B | Synthesis method of chiral 1-tetrahydronaphthalene amide compound | 南开大学 | 2025-12-09 | — | — | CN | disclosed |
| CN-120119268-B | Synthesis method of chiral 1-tetrahydronaphthalene amide compound | 南开大学 | 2025-12-09 | — | — | CN | disclosed |
| CN-120119268-A | Synthesis method of chiral 1-tetrahydronaphthalene amide compound | 南开大学 | 2025-06-10 | — | — | CN | disclosed |
| CN-120119268-A | Synthesis method of chiral 1-tetrahydronaphthalene amide compound | 南开大学 | 2025-06-10 | — | — | CN | disclosed |
| CN-120119268-A | Synthesis method of chiral 1-tetrahydronaphthalene amide compound | 南开大学 | 2025-06-10 | — | — | CN | disclosed |
| US-20240415819-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | QLi5 Therapeutics AG (DE) | 2024-12-19 | — | — | US | disclosed |
| CN-111278815-B | Glutarimide | C4医药公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-117285439-A | Phenylalanine amide derivatives as beta 2 Use of allosteric antagonists of adrenergic receptors | 常州大学 | 2023-12-26 | — | — | CN | disclosed |
| EP-4155296-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | Lead Discovery Center GmbH (DE) | 2023-03-29 | — | — | EP | disclosed |
| US-20220291237-A1 | Gene Expression Inflammatory Age and Its Uses | Edifice Health, Inc. (US) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240415819-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | PSMB5, PSMA5, PSMB1 | IDO1 2208/4885HTT 1871/4885ALDH1A1 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.